Race Oncology Ltd has released a press release.
June 2025 Quarterly Activity Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- RC220 Human Ethics Approvals Received in Hong Kong
- First Patient Safely Combine Dosed in Phase 1 RC220 Trial
- First Patient Dosed Safely in RC220 Phase 1 Trial
- March 2025 Quarterly Activity Report and Appendix 4C
- Enrolment Opened at Second Site for RC220 Phase 1 Trial
Later from Racura Oncology
- Appendix 4E & Annual Report
- First Hong Kong Site Activated for RC220 Trial
- Race Breakthrough Composition of Matter IP Discovery
- RC220 IND Approval from Korean MFDS
- Discovery of the Anticancer Mechanism of (EE)-bisantrene
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology